← Back to Search

Behavioural Intervention

Educational Intervention for Cancer Knowledge

N/A
Waitlist Available
Led By Stacy W Gray
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of lung, breast, colorectal, pancreatic, ovarian or prostate cancer
Having somatic, germline or paired somatic/germline sequencing
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12-month period after results disclosure
Awards & highlights

Study Summary

This trial studies a web-based cancer education tool called HOPE-Genomics. The tool provides patients with information about genomic testing and their own genomic test results. The goal is to improve patient's genomic knowledge and quality of patient-centered care.

Who is the study for?
This trial is for English-speaking adults over 18 with lung, breast, colorectal, pancreatic, ovarian or prostate cancer who are undergoing genomic sequencing. They must be enrolled in a specific review board and have a performance status indicating they can care for themselves.Check my eligibility
What is being tested?
The trial tests the HOPE-Genomics web tool designed to educate cancer patients about their own genomic test results and general genomics knowledge. It aims to see if this improves understanding of personal testing outcomes and overall patient-centered care quality.See study design
What are the potential side effects?
Since this study involves an educational intervention rather than medication or medical procedures, traditional physical side effects are not expected. Participants may experience information overload or stress related to learning about their genomic data.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with lung, breast, colorectal, pancreatic, ovarian, or prostate cancer.
Select...
My cancer has been genetically sequenced.
Select...
I am able to care for myself and perform daily activities.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12-month period after results disclosure
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12-month period after results disclosure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Recall rates of personal genomic results
Secondary outcome measures
Operationalization of contextual guideline concordant care
Other outcome measures
General genomic knowledge
Genetically-guided care
HOPE-Genomics tool usage
+1 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Arm III (HOPE-Genomics, genomics test results)Experimental Treatment2 Interventions
Patients view HOPE-Genomics tool (containing educational content) over 15-20 minutes before their sequencing results are available. Patients also receive their genomics test results both from their clinician and from the HOPE-Genomics tool.
Group II: Arm II (genomics test results, HOPE-Genomics)Experimental Treatment3 Interventions
Patients receive their genomics test results both from their clinician and from the HOPE-Genomics tool. Patients then view HOPE-Genomics tool over 15-20 minutes after their results are available.
Group III: Arm I (usual care)Active Control2 Interventions
Patients receive education pamphlet about WES and have their genomics test results returned by their clinician in a typical manner.

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor
558 Previous Clinical Trials
1,916,987 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,609 Previous Clinical Trials
40,915,181 Total Patients Enrolled
Stacy W GrayPrincipal InvestigatorCity of Hope Comprehensive Cancer Center
1 Previous Clinical Trials
240 Total Patients Enrolled

Media Library

HOPE-Genomics (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT04905082 — N/A
Colorectal Cancer Research Study Groups: Arm I (usual care), Arm II (genomics test results, HOPE-Genomics), Arm III (HOPE-Genomics, genomics test results)
Colorectal Cancer Clinical Trial 2023: HOPE-Genomics Highlights & Side Effects. Trial Name: NCT04905082 — N/A
HOPE-Genomics (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04905082 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are currently engaged in this research?

"Affirmative, the information posted on clinicaltrials.gov shows that this experiment is actively enrolling participants as of now. It was first uploaded December 30th 2021 and last revised February 11th 2022 to seek 435 subjects from 1 site."

Answered by AI

Are there any available openings for participation in this trial?

"Affirmative, the information provided on clinicaltrials.gov denotes that this trial is actively enlisting patients as of now. The study was first published on December 30th 2021 and updated recently on February 11th 2022, with a target enrollment goal of 435 subjects from 1 site."

Answered by AI
~46 spots leftby Jun 2024